Crossmark Global Holdings Inc. Sells 1,009 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Crossmark Global Holdings Inc. decreased its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 19.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,113 shares of the specialty pharmaceutical company’s stock after selling 1,009 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Jazz Pharmaceuticals were worth $439,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of JAZZ. Rise Advisors LLC boosted its position in shares of Jazz Pharmaceuticals by 2,255.6% during the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock worth $26,000 after purchasing an additional 203 shares in the last quarter. Versant Capital Management Inc lifted its holdings in Jazz Pharmaceuticals by 13,450.0% during the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after acquiring an additional 269 shares in the last quarter. GAMMA Investing LLC grew its stake in Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after acquiring an additional 116 shares during the period. Gladius Capital Management LP bought a new stake in shares of Jazz Pharmaceuticals in the second quarter worth about $33,000. Finally, Cape Investment Advisory Inc. raised its position in shares of Jazz Pharmaceuticals by 14,600.0% during the fourth quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock worth $36,000 after purchasing an additional 292 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analyst Upgrades and Downgrades

JAZZ has been the subject of a number of research reports. Royal Bank of Canada lowered their target price on Jazz Pharmaceuticals from $175.00 to $174.00 and set an “outperform” rating for the company in a research note on Thursday, August 1st. Piper Sandler dropped their price objective on shares of Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a report on Thursday, August 1st. The Goldman Sachs Group initiated coverage on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 5th. They issued a “buy” rating and a $169.00 target price for the company. Robert W. Baird dropped their price target on Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a research note on Thursday, August 1st. Finally, Morgan Stanley cut their price target on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating on the stock in a report on Friday, July 12th. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $173.07.

Jazz Pharmaceuticals Stock Up 0.3 %

JAZZ stock opened at $115.98 on Tuesday. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $146.70. The company has a market cap of $7.31 billion, a price-to-earnings ratio of 23.91, a P/E/G ratio of 1.45 and a beta of 0.58. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. The business has a 50 day moving average price of $109.67 and a two-hundred day moving average price of $112.65.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.